Phase 3 Study Demonstrates Intracranial Response in ALK+ NSCLC
Benjamin Solomon, MBBS, PhD, discusses the intracranial responses observed in the CROWN trial of lorlatinib versus crizotinib in patients with ALK-positive non–small cell lung cancer.